🎉 Gate Square — Share Your Funniest Crypto Moments & Win a $100 Joy Fund!
Crypto can be stressful, so let’s laugh it out on Gate Square.
Whether it’s a liquidation tragedy, FOMO madness, or a hilarious miss—you name it.
Post your funniest crypto moment and win your share of the Joy Fund!
💰 Rewards
10 creators with the funniest posts
Each will receive $10 in tokens
📝 How to Join
1⃣️ Follow Gate_Square
2⃣️ Post with the hashtag #MyCryptoFunnyMoment
3⃣️ Any format works: memes, screenshots, short videos, personal stories, fails, chaos—bring it on.
📌 Notes
Hashtag #MyCryptoFunnyMoment is requi
Two late-stage studies of Merck's HIV therapy have met primary goals
On December 19th, Jinshi Data reported that Merck announced on Thursday that its experimental combination therapy for some adult HIV-1 patients has achieved the primary efficacy and safety goals in two late-stage studies. The company stated that its Doravirine/Islatravir combination therapy is not inferior to Gilead Sciences’ triple combination tablet Biktarvy and other various antiretroviral therapies in terms of viral replication inhibition. Merck plans to submit the data to regulatory authorities and present detailed research results at future medical conferences.